||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
-/ 1440 Barberry Dr. PT COQ BC V3B1G3 CA
Toll free: +011-604-941-9022 (help line)
Phone: +011-604-945-8408 (landline)
Fax: +011-604-941-9022 (FAX line)
Developmental Biology & Physiology: the basis for Cell/Molecular Biology
The use of a unified approach in Developmental Biology or Physiology at the cellular level to undertake the understanding of the basis of all cellular phenomena from the: cell's life span and longevity; cellular repair and remission from diseased states; growth and development, energetics, efficiency and productivity; and activatable states for therapeutic applications (e. g. anti-viral therapies).
Research Areas we are pursuing that are sourced from our own experiments and the scientific literature:
- Models to study are cell activatable therapeutics (CATs) and the immune system using experimental sheep modeling.
- The lower molecular weight [LMW] proteome and new pharma to discover with musco-regulatory factors (MRFs) and muscle tissue development and regulation for productive end products and health.
- The use of lithium and umbilical cord blood cells to restore function in chronic complete spinal cord injury.
- Speculation of a role for energy efficiency utilization at the cellular level and the role of p38 and alpha tissue necrotic factors (alpha-TNF) and mitogenesis and longevity or lifespan. There is research continuing in this area at the Medical Faculty, UNSW, Sydney, Australia NSW 2033.
- VitD and fructan and their interactions with p38 and their role in modulating the chronic inflammatory response as it impacts disease states such as: atherosclerosis, T2Diabetes, hypertension, and multiple sclerosis with new pharma to be discovered.
- Fructan and APPs and their role in determining the efficiency of microbial biomass turnover in ungulates; this as a model has also applications to efficiency in productivity of farming animals and should be of interest at the U. of New England, Armidale NSW (AU) 2351 in their Large Animal Research Unit (LARU) for energetics livestock research in future.
E.G.S. of Projects:
a) Immunogeneic delivery systems (e. g. for cancers) with the ARC, Agri-Food Canada, Ottawa ON Canada.
b) Search with a Physiological Assay Protocol for VitD and Fructan Nutritionals and their Parallel Metabolites as Putative Drug Targets. TF activation or expression with cell systems characteristic of Vit D and inulins that have been studied previously should be assayed using the oligonucleotide array-based transcription factor assay (OATFA) system and their associated gene products (i. e. enzymes, structural proteins, transport proteins, etc.) characterized from a molecular biological standpoint in order to discover and characterize targets for drugs. Drug design in tandem with X-ray crystallographic/cryo-transmission electron microscopy studies and synthesis and clinical trials follows. It was stipulated that although drugs would target molecules involved with specific non-immunogeneic response so as not to lower below the norm, that drugs perhaps affect other specific functions affecting inflammation in some other way. Assay to assess immune status is by T cell, macrophage and cytokine levels in test animals from the site of infection.
The tantamount question is: what therapeutic modalities, e. g. including genetic counselling & therapy, stem transplantation cell therapy, that will emerge from research from this vast and new, unified theory encompassing cell development & physiology, and its attendant pharma, especially from the mind-body axies [viz., brain<->organosomal systems or axies & interlinks] to be discovered and their analysis in the depleted plasmoidal (and plasmoidal-like) - [LMW] proteome is expected to come to pass in the near future.
Drug Discovery with Boosted Dairy Lactoferrin Using Small Molecule Biopharma for Heart Health.
It was quoted recently from a paper that, "The question that confronts the issue of manipulating dairy lactoferrin in milk in terms of composition (and as it would also follow, total output), significantly boost medicinal-conferring milk food proteins (e. g. casein, alpha-lactalbumin and lactoferrin are examples of those of interest in the scientific literature) which likely serve a protective role against chronic inflammation, is with what therapeutic drug discovery using small molecular tools can we carry our search further with?" [D. A. Flores. 2016. Editorial. Biomolecular and Medicine J. @ dannflores9. wordpress.com.] It is believed at Skye Blue that small molecular analogues to p38, a molecule that addresses the 'suite' of chronic inflammatory markers [D. A. Flores. 2013. Overview Paper. Biomolecular and Medicine J. @ dannflores7.wordpress.com], that are 'recalcitrant' to breakdown could be used therapeutically for heart-health, for example, by single amino acid residue substitutions without affecting tertiary considerations to subunit and allosteric structure or function.
Boosting Milk Proteins with Medicinal Properties for Heart Health: the Search for Transcription Factors to Caprine Lactoferrin.
The modern molecular genetics of caprine (goatary) dairy function (viz. yield or output, milk contents or composition, %) has advanced in recent years, since 2012, with finds elucidating the SNP (single nuclear polymorphisms or mutations) in DNA with chromosomal (c'somal) position (viz. their numbering). Microsatellite tracts consisting of repetitive DNA sequences with certain DNA motifs are repeated 5-50X (times) with DNA microarrays- point oligo-DNA arrays as probes binding to cDNA or cRNA called targets that are appropriately labelled, used for fine-mapping quantitative trait loci (QTL) determinations, or how significantly a QTL point locus correlates statistically with a phenotypic parameter; however, there have been limitations from "old school" standpoints regards low resolution limited by the statistical confidence limit intervals to a certain significance level. A recent study reported by Shopen et al. (2011) [in Marcel Amills et al., 2012, Genetic Factors that Regulate Milk Protein and Lipid Composition in Goats, Intech, Chap. 1], demonstrated significant association between loci in c'some 5, 6, 11, & 14 to milk protein composition. For our purposes at Skye Blue of producing GMO goats with boosted caprine lactoferrin (cLF) milk protein for medicinal purposes, a preliminary find that points to regulatory genes (transcription factors or TFs) is a trans-effect in bovine cattle that could apply to sheep and goats of an SNP locus affecting c'some 11 &14 for alpha-casein unit one protein (a major casein protein) while residing in position c'some 6.
SKYE BLUE INTERNET ®
Information in Companies. Working for Information.
Made for Information. ®
All copyright held by D. A. Flores. 2003-2016. All rights reserved. Disclaimer.
Last update of this entry: May 03, 2018